Characteristics of all transplant recipients and patient subgroups
| . | All, n (%) . | Hypergammaglobulinemia, n (%) . | Hypogammaglobulinemia, n (%) . | Normogammaglobulinemia, n (%) . |
|---|---|---|---|---|
| No. of patients | 76 | 25 | 21 | 30 |
| Median age, y (range) | 40 (23-59) | 39 (23-54) | 40 (23-51) | 42 (29-59) |
| Sex | ||||
| Male | 41 | 16 | 12 | 13 |
| Female | 35 | 9 | 9 | 17 |
| Diagnosis | ||||
| Acute leukemia | 36 | 13 | 10 | 13 |
| Chronic myeloid leukemia | 14 | 4 | 4 | 6 |
| Malignant lymphoma | 14 | 4 | 5 | 5 |
| Other* | 12 | 4 | 2 | 6 |
| Disease status at transplantation† | ||||
| Standard risk | 43 | 14 | 9 | 20 |
| High risk | 33 | 11 | 12 | 10 |
| Conditioning regimen | ||||
| Myeloablative | 45 | 13 | 12 | 20 |
| Reduced intensity | 31 | 12 | 9 | 10 |
| Stem cell donors | ||||
| Related | 24 | 9 | 6 | 9 |
| Unrelated | 52 | 16 | 15 | 21 |
| HLA-identical | 66 | 21 | 19 | 26 |
| HLA-mismatched | 10 | 4 | 2 | 4 |
| Stem cell source | ||||
| Bone marrow | 6 | 2 | 2 | 2 |
| Peripheral blood | 70 | 23 | 19 | 28 |
| Median no. CD34+ cells × 106/kg transplanted (range) | 5.6 (0.9-10.4) | 6.5 (2.9-10.4) | 5.9 (1.7-8.2) | 5.6 (0.9-7.6) |
| Posttransplantation immunosuppressive prophylaxis | ||||
| Cyclosporine only | 4 | 0 | 1 | 3 |
| Cyclosporine-methotrexate | 41 | 14 | 14 | 13 |
| Cyclosporine-mycophenolate mofetil | 31 | 11 | 6 | 14 |
| Acute GVHD | ||||
| Grade 0 | 32 | 7 | 8 | 17 |
| Grade I or II | 26 | 10 | 8 | 8 |
| Grade III or IV | 18 | 8 | 5 | 5 |
| . | All, n (%) . | Hypergammaglobulinemia, n (%) . | Hypogammaglobulinemia, n (%) . | Normogammaglobulinemia, n (%) . |
|---|---|---|---|---|
| No. of patients | 76 | 25 | 21 | 30 |
| Median age, y (range) | 40 (23-59) | 39 (23-54) | 40 (23-51) | 42 (29-59) |
| Sex | ||||
| Male | 41 | 16 | 12 | 13 |
| Female | 35 | 9 | 9 | 17 |
| Diagnosis | ||||
| Acute leukemia | 36 | 13 | 10 | 13 |
| Chronic myeloid leukemia | 14 | 4 | 4 | 6 |
| Malignant lymphoma | 14 | 4 | 5 | 5 |
| Other* | 12 | 4 | 2 | 6 |
| Disease status at transplantation† | ||||
| Standard risk | 43 | 14 | 9 | 20 |
| High risk | 33 | 11 | 12 | 10 |
| Conditioning regimen | ||||
| Myeloablative | 45 | 13 | 12 | 20 |
| Reduced intensity | 31 | 12 | 9 | 10 |
| Stem cell donors | ||||
| Related | 24 | 9 | 6 | 9 |
| Unrelated | 52 | 16 | 15 | 21 |
| HLA-identical | 66 | 21 | 19 | 26 |
| HLA-mismatched | 10 | 4 | 2 | 4 |
| Stem cell source | ||||
| Bone marrow | 6 | 2 | 2 | 2 |
| Peripheral blood | 70 | 23 | 19 | 28 |
| Median no. CD34+ cells × 106/kg transplanted (range) | 5.6 (0.9-10.4) | 6.5 (2.9-10.4) | 5.9 (1.7-8.2) | 5.6 (0.9-7.6) |
| Posttransplantation immunosuppressive prophylaxis | ||||
| Cyclosporine only | 4 | 0 | 1 | 3 |
| Cyclosporine-methotrexate | 41 | 14 | 14 | 13 |
| Cyclosporine-mycophenolate mofetil | 31 | 11 | 6 | 14 |
| Acute GVHD | ||||
| Grade 0 | 32 | 7 | 8 | 17 |
| Grade I or II | 26 | 10 | 8 | 8 |
| Grade III or IV | 18 | 8 | 5 | 5 |
HLA indicates human leukocyte antigen.
Other diagnoses included myelodysplastic syndrome and chronic lymphocytic leukemia.
Standard risk was defined as acute leukemia in first or second complete remission or chronic myeloid leukemia in first chronic phase. High-risk disease included myelodysplastic syndrome and advanced stage of acute and chronic leukemia and malignant lymphoma.